Azacitidine

From OncoWiki
Jump to: navigation, search

Drug information

Azacitidine drug information (Vidaza, Pharmion)

Indications

Myelodysplastic Syndromes

75 mg/m2/d sc qd x 7 days q4w


First Treatment Cycle

  • The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
  • Patients should be premedicated for nausea and vomiting.


Subsequent Treatment Cycles

  • Cycles should be repeated every 4 weeks.
  • For both SC and IV, the dose may be increased to 100 mg/m2 if no beneficial effect is seen after 2 treatment cycles and if no toxicity other than nausea and vomiting has occurred.
  • It is recommended that patients be treated for a minimum of 4 cycles. However, complete or partial response may require more than 4 treatment cycles.
  • Treatment may be continued as long as the patient continues to benefit.


References

Silverman LR et al. Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20:2429